These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25043591)

  • 1. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.
    de la Croix Ndong J; Stevens DM; Vignaux G; Uppuganti S; Perrien DS; Yang X; Nyman JS; Harth E; Elefteriou F
    J Bone Miner Res; 2015 Jan; 30(1):55-63. PubMed ID: 25043591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
    Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
    Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells.
    El-Hoss J; Sullivan K; Cheng T; Yu NY; Bobyn JD; Peacock L; Mikulec K; Baldock P; Alexander IE; Schindeler A; Little DG
    J Bone Miner Res; 2012 Jan; 27(1):68-78. PubMed ID: 21956219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
    El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
    J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JNK inhibitors increase osteogenesis in Nf1-deficient cells.
    Sullivan K; El-Hoss J; Little DG; Schindeler A
    Bone; 2011 Dec; 49(6):1311-6. PubMed ID: 21964323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.
    Rhodes SD; Wu X; He Y; Chen S; Yang H; Staser KW; Wang J; Zhang P; Jiang C; Yokota H; Dong R; Peng X; Yang X; Murthy S; Azhar M; Mohammad KS; Xu M; Guise TA; Yang FC
    J Bone Miner Res; 2013 Dec; 28(12):2476-89. PubMed ID: 23703870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.
    Paria N; Cho TJ; Choi IH; Kamiya N; Kayembe K; Mao R; Margraf RL; Obermosser G; Oxendine I; Sant DW; Song MH; Stevenson DA; Viskochil DH; Wise CA; Kim HK; Rios JJ
    J Bone Miner Res; 2014 Dec; 29(12):2636-42. PubMed ID: 24932921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The reduced osteogenic potential of Nf1-deficient osteoprogenitors is EGFR-independent.
    Tahaei SE; Couasnay G; Ma Y; Paria N; Gu J; Lemoine BF; Wang X; Rios JJ; Elefteriou F
    Bone; 2018 Jan; 106():103-111. PubMed ID: 29032173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.
    Wang W; Nyman JS; Ono K; Stevenson DA; Yang X; Elefteriou F
    Hum Mol Genet; 2011 Oct; 20(20):3910-24. PubMed ID: 21757497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Status of
    Peacock JD; Pridgeon MG; Tovar EA; Essenburg CJ; Bowman M; Madaj Z; Koeman J; Boguslawski EA; Grit J; Dodd RD; Khachaturov V; Cardona DM; Chen M; Kirsch DG; Maina F; Dono R; Winn ME; Graveel CR; Steensma MR
    Cancer Res; 2018 Jul; 78(13):3672-3687. PubMed ID: 29720369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Catenin modulation in neurofibromatosis type 1 bone repair: therapeutic implications.
    Ghadakzadeh S; Kannu P; Whetstone H; Howard A; Alman BA
    FASEB J; 2016 Sep; 30(9):3227-37. PubMed ID: 27306335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Dissection of Somatic Skeletal Disease in Neurofibromatosis Type 1.
    Paria N; Khalid A; Shen B; Lemoine B; Chan J; Kidane YH; Oxendine I; Cornelia R; Wise CA; Rios JJ
    J Bone Miner Res; 2023 Feb; 38(2):288-299. PubMed ID: 36459048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.
    de la Croix Ndong J; Makowski AJ; Uppuganti S; Vignaux G; Ono K; Perrien DS; Joubert S; Baglio SR; Granchi D; Stevenson DA; Rios JJ; Nyman JS; Elefteriou F
    Nat Med; 2014 Aug; 20(8):904-10. PubMed ID: 24997609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
    Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
    Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.
    Staser K; Park SJ; Rhodes SD; Zeng Y; He YZ; Shew MA; Gehlhausen JR; Cerabona D; Menon K; Chen S; Sun Z; Yuan J; Ingram DA; Nalepa G; Yang FC; Clapp DW
    J Clin Invest; 2013 Jan; 123(1):329-34. PubMed ID: 23221339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
    Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
    Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein-2 and zoledronic acid.
    Deo N; Cheng TL; Mikulec K; Peacock L; Little DG; Schindeler A
    J Orthop Res; 2018 Mar; 36(3):930-936. PubMed ID: 28767180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1.
    Mund JA; Park S; Smith AE; He Y; Jiang L; Hawley E; Roberson MJ; Mitchell DK; Abu-Sultanah M; Yuan J; Bessler WK; Sandusky G; Chen S; Zhang C; Rhodes SD; Clapp DW
    J Biol Chem; 2020 Jul; 295(29):9948-9958. PubMed ID: 32471868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair.
    Baht GS; Nadesan P; Silkstone D; Alman BA
    Bone; 2017 May; 98():31-36. PubMed ID: 28254468
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Pucciarelli D; Angus SP; Huang B; Zhang C; Nakaoka HJ; Krishnamurthi G; Bandyopadhyay S; Clapp DW; Shannon K; Johnson GL; Nakamura JL
    Mol Cancer Ther; 2020 Nov; 19(11):2382-2395. PubMed ID: 32847978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.